The tumorigenic potential of phenobarbital was examined in a 26-wk carcinogenesis bioassay using p53 heterozygous mice and wild-type controls. Fifteen mice/sex/genotypc were exposed to either 500 or 1, OOO ppm phenobarbital in the diet. Dietary administration of 3,750 ppm p-cresidine, a transspecies mutagenic carcinogen, to both heterozygous and wild-type mice served as a positive control. Phenobarbital treatment caused increases in liver: body weight ratios and histologic evidence of centrilobular hepatocellular hypertrophy. No tumors were observed in any phenobarbital-treated mice. Mice given p-cresidine exhibited a moderate reduction in body weight gain over the c o u m of the study. Heterozygous mice treated with p-cresidine exhibited a high incidence of urinary bladder tumors. Similar tumors were also present in a small number of p-cresidinc-treated wild-type mice. Our results demonstrate the lack of a hepatic tumor response to phenobarbital, a compound that is a potent and prototypic hepatic microsomal enzyme inducer, a nongenotoxic rodent carcinogen, and a human noncarcinogen. This finding supports the continued utility of this model as an alternative to the mouse bioassay for human carcinogenic safeJy assessment of potentially genotoxic carcinogens because it did not produce a false-positive response to this potent nongenotoxic agent.
INTRODUC~ION
The lifetime rodent cancer bioassay has benefited society over the past decades. Human life expectancy continues to increase without generally recognized correlative increases in age-adjusted tumor rates. Thirty years of learning in our cancer hazard identification studies can now be leveraged to improve our safety assessment processes. We now recognize that lifetime mouse cancer studies do not substantially impact the safety assessment of pharmaceuticals beyond that provided by genetic toxicity studies and acute, subchronic, and chronicnifetime rat studies (2). We are not aware of any mouse-cancerpositiveht-negative human carcinogen that could not have been predicted based on short-term in v i m tests or short-term and lifetime rat studies.
The international pharmaceutical community now recognizes alternatives to the lifetime mouse cancer study as acceptable (15) . The acceptable alternatives are basically iiz vivo studies with tumor end points using genetically altered mice to increase their sensitivity and shorten the latency to cancer end points. An international consortium under the auspices of the International Life Sciences Institute (ILSI) is conducting studies of well-characterized pharmaceuticals and chemicals to enable definition of the conditions appropriate for the use of 4 widely recognized alternative mouse models: the p53 heterozygous mouse, Tg.AC transgenic mouse, rusH2 transgenic mouse, and XPA-deficient mouse (25) .
In selecting a new model, concordance with human carcinogenesis is prerequisite. Development of positive responses to agents that are not human or rodent carcinogens would certainly mitigate against use of the model because the false-positive rate for cancer hazard identification in traditional rodent testing is already high. The majority of rodent responses to pharmaceutical agents are not..considered predictive for humans (2). A genetically altered mouse model that is negative for rodent carcinogens that are also human noncarcinogens would certainly be an improvement on traditional testing. Of course, society would still benefit if the new model only demonstrated high concordance with traditional rodent carcinogenesis studies because the genetically altered models will reduce the time to product registration and result in the use of significantly fewer total animals (estimated at 30% fewer) than would typically be used in the safety assessment program of a pharmaceutical agent intended for chronic use.
The p53 heterozygous mouse model conceptually represents an intriguing opportunity to improve the cancer hazard identification process. p53 is the most frequently altered gene in human cancers (5, 14) , and is an important negative regulator of cell growth (20) and gene expression (10, 28) . Experimentally, the p53 heterozygous mouse model has shown good concordance with genotoxic rodent carcinogens (29.30) . We tested this model with the prototype liver tumor promoter phenobarbital as part of the ILSI consortium activity. Phenobarbital is generally recognized as a nongenotoxic agent that is a potent liver carcinogen in mice (24) . a potent liver tumor promoter in the rat (8, 23) , and a noncarcinogen in humans (22) .
(lot 36551, Pfaltz and Bauer, Waterbury, CT) were administered in powdered Certified Rodent Chow 5002 (PMI, St. Louis, MO). The p-cresidine diet was prepared once weekly; p-cresidine was dissolved in acetone before being mixed into chow. The phenobarbital diet was prepared every 2 wk by direct mixing of phenobarbital into chow. Analytical tests of prepared diets indicated that uniformity of mixing and compound concentration were within acceptable ranges for both phenobarbital and pcresidine (data not shown).
Animals. C57BL/6TacfBR-[KO]p53' and C57BL/ 6TacfBR mice of both sexes, approximately 4-6 wk old on arrival (Taconic, Germantown, NY) were acclimated for 14 days before dosing began. Tail biopsies were obtained from 10% of mice of each genotype and returned to the animal supplier for blind genotype verification by Southern blot analysis; 100% concordance was achieved in the genotype verification. Mice were housed individually in suspended stainless steel wire-mesh cages in animal rooms with temperatures of 22°C 2 3°C and relative humidity of 50% +-20%, with an approximate 12-hr light, 12-hr dark cycle. Rodent chow and tap-water were. available ad libitimt. Animals of each sex and genotype were randomly assigned to treatment groups using a procedure designed to achieve balance with respect to the last available pretreatment body weight. Animals not in good physical condition or with body weight extremes were not assigned to the study. Group body weight means were checked for comparability following randomization. Study Design. Fifteen mice/sex/group were treated for 26 wk with p-cresidine or phenobarbital in feed. Each compound was tested in both p53 heterozygotes (+/-) and in the C57BL/6 background strain (+/+), which carries 2 copies of the normal p53 gene. Negative control diet-fed mice of each genotype were also included in the study. Phenobarbital was administered at dose levels of 500 and 1,000 ppm (17, 30) . The 500-ppm dose level has been shown to be hepatocarcinogenic in mice (31) . The higher dose level was also chosen because of the relative resistance of C57BL/6 mice to liver tumor promotion (6) . p-Cresidine was administered at 2,500 ppm for 1 wk to acclimate the mice to the test compound (30) . The dose level of p-cresidine was then raised to 5,000 ppm for 1 wk; however, because of severe body weight loss by all p-cresidine-treated mice, the dose level was reduced back to 2,500 ppm for the next 2 wk. The p-cresidine dose level was then raised to 3,750 ppm; dosing at this concentration was maintained for the remainder of the study. Dosing of all groups continued until approximately 21-28 hr prior to necropsy.
Morphologic Evalidation. Complete necropsies were performed and tissues were collected from all mice that survived to the end of the study. Brain, heart, kidneys, liver, ovaries, testes, urinary bladder, and uterus were weighed prior to fixation. The following organs were immersion fixed in 10% neutral buffered formalin, processed routinely, sectioned, stained with hematoxylin and eosin (H&E), and examined microscopically: liver, urinary bladder, kidney, brain, skeletal muscle, sciatic nerve, spinal cord, spleen, salivary gland, submaxillary lymph 
RESULTS

Sitrvival
When survival data from both genotypes and both sexes were combined, all groups, including those fed a normal diet, had a 97% survival rate (58/60 total mice/ group). There was no obvious adverse effect of treatment with either phenobarbital or p-cresidine that affected overall survival rates. One p-cresidine treated heterozygous male mouse died from hydronephrosis, likely secondary to renal papillary necrosis (as observed in other mice from the same group) but unidentified because of severe autolysis. Survival data and causes of death are summarized in Table I .
Body and Orgaii Weights
Mice of both sexes and both genotypes exposed to pcresidine showed a reduction in weekly body weight gain beginning with a severe weight change after 1 wk at 5,000 pprn ( Fig. 1 ). This sharp decrease in body weight prompted dose adjustments, after which there were no further body weight losses for the remainder of the study. However, body weight gain in the p-cresidine-treated mice was slower than that for control or phenobarbitaltreated mice of both sexes and both genotypes. Terminal body weights of the p-cresidine-treated mice were significantly lower than those for genotype-matched controls for both sexes. The terminal body weights for control diet-fed heterozygous male mice were significantly greater than those for control diet-fed wild-type male mice ( Fig. 1 ).
All groups of phenobarbital treated mice showed a significant increase in absolute and relative liver weights (Fig. 2) . This change was most pronounced in the high dose (1,000 ppm) phenobarbital mice of both sexes and both genotypes. There was no significant difference in liver : body weight ratios between heterozygous and wild-TOXICOLOGIC PATHOLOGY Body weights of heterozygous male mice was escalated to 5.000 ppm during week 2. Following dose adjustment, body weight gain resumed but at a slower rate than in controls. Heterozygous male mice fed a control diet had significantly higher terminal body weights than did wild-type male mice fed the control diet @ < 0.01). Terminal body weights of phenobarbital-treated and p-cresidine-treated heterozygous male mice were significantly lower than those of genotype-matched controls (shaded bars represent heterozygous mice and solid bars represent wild-type mice). Terminal body weights of p-cresidine-treated wild-type males and both genotypes of females were significantly lower than those of controls. 0 = control diet; A = phenobarbital (500 ppm); X = phenobarbital (1,000 ppm); 0 = p-eresidine. *p < 0.05: **p < 0.01 versus genotype-matched controls. type mice. In wild-type male mice treated with p-cresidine, a slight but significant increase in absolute liver weight was also observed. The increase in relative liver weights of mice treated with p-cresidine was significant in all groups, primarily because of the decreases in terminal body weights (Fig. 2) .
Histopathology Findings
Phenobarbital. There were no tumors in mice of either sex or genotype treated with phenobarbital. The livers of all animals of both sexes and both genotypes exhibited moderate to marked centrilobular hepatocellular hypertrophy (Fig. 3B) , a finding consistent with the observed increase in absolute and relative liver weights (Fig. 2 ) and interpreted as secondary to robust metabolic enzyme induction.
p-Cresidine. Treatment-related histopathology findings were observed in the lower urinary tract, liver, and kidney of p-cresidine-treated mice. Histopathology findings in the urinary bladder are shmmarized in Table 11 -and illustrated in ' Fig. 3D . A progression of proliferative lesions from diffuse transitional epithelial hyperplasia, pre-I dominantly sessile and exophytic, to focal dysplasia was observed. Squamous metaplasia of the transitional epithelium was present in mice of both sexes and genotypes. Transitional cell carcinomas were observed in the urinary bladder of 10/14 (71%) heterozygous males and 11/15 (73%) heterozygous females. An additional heterozygous male had a transitional cell carcinoma in the prostatic urethra. These tumors were frequently accompanied by moderate desmoplasia and mild lymphohistiocytic inflammatory infiltrate. One of 15 (7%) wild-type males and 1/15'(7%) wild-type females also had transitional cell carcinomas of the urinary bladder histologically identical to those observed in heterozygotes.
Midzonal to penportal hepatocellular hypertropGy of moderate to marked seventy was present in all p-cresidine-treated mice of both genotypes (Fig. 3C) . Individualized hepatocellular death (apoptotic necrosis) and disruption of trabecular architecture was frequently present within these areas of hypertrophy, suggesting that underlying hepatotoxicity may have contributed to the liver tumor responses observed in other studies (29, 30) . No TOXICOLOGIC PATHOLOGY tumors were identified in the livers of p-cresidine-treated mice in our study.
In the kidneys of p-cresidine-treated mice, renal papillary necrosis was observed in 3/15 heterozygous males, 7/15 wild-type males, 5/15 heterozygous females, and 71 15 wild-type females. In the heterozygous males, an additional 4 animals exhibited hydronephrosis, obscuring the ability to make an observation in the renal papilla.
One heterozygous male mouse treated with p-cresidine had a thymic lymphosarcoma with infiltration into the intercostal musculature. The singular incidence of this finding coupled with an emerging recognition of lymphosarcoma as a common spontaneous neoplasm in p53 heterozygous mice argues against its relationship to treatment.
A single male heterozygous mouse treated with p-cresidine exhibited a focal area of atypical osteoblastic proliferation within the cranium. This lesion consisted of an intraosseous proliferation of atypical osteoblasts with erosion of cortical bone at its periphery and production of well-differentiated woven bone at its center. In a female heterozygous mouse treated with p-cresidine, a similar lesion was observed in the cortex of a sternebra. Again, the singular occurrence of this lesion in each of these groups does not constitute a treatment effect.
Additional histopathology data from control animals (both heterozygous and wild-type) is summarized in Table 111. Although many observations represented here are not necessarily unique to this strain or genotype, this table is intended to document the background histopathology findings in mice of this strain for future reference. The data included in this table represent those diagnoses recorded in 2 2 mice from any control group.
DISCUSSION
The lack of a phenobarbital-related tumorigenic response in the liver of p53 heterozygous mice supports the continued examination of this model as an alternative to the 2-yr mouse bioassay. Phenobarbital, a potent and prototypic hepatic microsomal enzyme inducer (6), has been well described as a positive tumorigenic agent in the mouse liver (24) and is a rat thyroid and liver tumor promoter (8, 19,23) . However, epidemiologic data do not support a role for phenobarbital as a human carcinogen (20) . Because the ultimate purpose of carcinogenesis bioassays is to predict human cancer risk, the p53 heterozygous mouse model is attractive in its potential to eliminate false-positive responses for human carcinogen& risk with molecules of this class.
The ability of the p53 heterozygous mouse assay to identify genotoxic agents was confirmed in this study. Both heterozygous and wild-type mice exhibited a positive urinary bladder tumor response to p-cresidine in addition to mucosal epithelial hyperplasia, dysplasia, and squamous metaplasia. Heterozygous mice of both sexes exhibited a markedly accentuated bladder tumor response, as indicated by increased incidence of tumors in mice of this genotype. Previous reports have not identified the potential of p-cresidine to induce urinary bladder tumors in wild-type mice within this time frame. The incidence of urinary bladder tumors in heterozygous female mice in our study was much higher (73% vs 20%) than that in a previous report (29). The dosing regimen chosen may partially explain this increased incidence.
In our study and others (30), short-term low dose exposure was used to acclimate mice prior to dose escalation. In addition, differences in age at study initiation in our experiment (6-8 wk) as compared with a previous study [15-18 wk (29)] may also have contributed to the increased incidence of urinary bladder tumors in female heterozygotes and their occurrence in both sexes of wild-type mice. In our study, we did not reproduce the weak positive liver tumor response to p-cresidine observed in female mice in the 2-yr mouse bioassay nor that observed in male p53 heterozygous mice in a previous report (30). Foci of atypical osteoblastic proliferation were observed within cortical bone of the cranium and sternum in 1 male and 1 female heterozygous mouse, respectively, exposed to p-cresidine. This lesion is similar to spontaneous fibro-osseous proliferation observed in female B6C3F, mice, both in its histologic features and in its skeletal distribution (1). Although these changes were not interpreted as treatment related, they are noteworthy because of the occurrence in a male mouse (in contrast to fibro-osseous proliferation in female B6C3F, mice) and because of the high incidence of well-differentiated osteosarcoma occurring in the axial skeleton of aged p53 , heterozygous mice (13). p53 mutations (17) and immunohistochemical overexpression of p53 protein (27) have been documentedrin the majority of human and canine osteosarcomas, respectively. If the observed findings represent preneoplastic changes, they would be expected to occur sporadically in p53 heterozygous mice in the course of the 26-wk bioassay.
The lack of a liver tumor response in p53 heterozygous mice after a 26-wk exposure period to phenobarbital is not unexpected. Mutations in p53 are not observed in spontaneous or chemically induced liver tumors of mice (1 1, 16, 26 ) and liver tumors are not a component of the spontaneous tumor spectrum observed in homozygous p53 "knock out" mice (12). Furthermore, the genetic background (C57BL/6) on which the p53 heterozygous mice are maintained has been shown to be more resistant to phenobarbital-promoted liver tumors initiated by Nnitrosodiethylamine (7) . Therefore, p53 heterozygous mice, presumably more sensitive to somatic events inactivating the remaining wild-type allele, would not be expected to exhibit a liver tumor response unless genetic lesions disrupting the wild-type allele were confounded by additional alterations in other regulatory genes. However, other epigenetic mechanisms (e.g., hypermethylation) may cause tumor suppressor gene inactivation without direct genetic damage (3, 21) . Phenobarbital is a powerful inducer of hepatic micro-soma1 enzymes (6). This induction is of sufficient magnitude to increase liver growth, which persists for the duration of testing. Additional agents that share these bi-ological characteristics when administered continuously are also mouse liver tumorigens and rat liver tumor promoters but weak liver tumorigens when administered without prior exposure to initiating chemicals. Prominent examples include doxylamine, an over-the-counter pharmaceutical, and loratadine and cetirizine, 2 antihistamines recently approved by the U.S. Food and Drug Administration. The consistency of this relationship suggests a common link between induction of hepatic metabolizing enzymes and the kodent liver tumorigenic response. Such a mechanism of rodent liver tumorigenesis is the most common single explanation for rodent liver carcinogenesis. A recent review of 138 chemicals in the mouse indicated a clear relationship between hepatomegaly and liver tumorigenesis, with 37 positive liver tumor responses (4). The explanation for a liver weight increase in the absence of toxicity is typically sustained metabolic enzyme induction. Because the prototype agent, pheno-barbital, is generally recognized as a human noncarcinogen, the mechanism by which phenobarbital causes rodent tumors is probably the most important explanation for the high rate of rodent false-positive carcinogens in traditional bioassays. Thus, although concordance of the genetically altered short-term mouse bioassay with the lifetime mouse bioassay for phenobarbital would be acceptable in terms of diminished animal usage and decreased time and resource expenditures, the absence of a positive response to phenobarbital suggests an improved model that could decrease the high false-positive rodent liver tumor response.
In previous testing, the tumor responsiveness of the p53 heterozygous mouse model has shown high concordance with genotoxic rodent carcinogens (29). Since this early report, an additional 9 chemicals have been tested (9) and have shown high concordance between the predicted and observed outcomes of the p53 bioassay in response to a variety of chemicals and pharmaceuticals. Thus, the relationship between genotoxic rodent carcinogenic responses and positive p53 heterozygous mouse bioassay results and similarly the lack of a p53-positive response for nongenotoxic rodent carcinogens or noncarcinogens initially proposed by Tennant et a1 (29) continues to be observed. Our data further strengthen this relationship. Results from this model should therefore be of greatest impact in the cancer risk assessment of new molecules when prior iiz vitro or iit vivo data create uncertainty as to whether the test agent has the potential to act as a genotoxic rodent carcinogen. This 26-wk p53 heterozygous mouse bioassay has shown conformity with human epidemiologic data with respect to the lack of a human tumor risk of phenobarbital and has not introduced rodent-specific carcinogenic responses to confound human risk assessment. Such a study design and experimental outcome is consistent with industry and governmental efforts to make the long-term safety assessment process more predictive of human risk, less prone to false-positive errors, timely, and economical in experimental animal usage.
